Related Experiment Videos
Interferon-gamma treatment of metastasized malignant melanoma
Abstract:
Between 1-1-85 and 6-30-86, 17 patients suffering from metastatic malignant melanoma received total doses of 30-40 I.U. IFN-gamma given i.v. in a daily fractionation of 1.0-2.6 X 10(6) I.U. The only side effect was fever grade I-II (WHO). In four of these patients a regression of the disease was obtained (two complete remissions and two partial remissions, according to UICC criteria). Thus, the overall response rate was 23.5%. The average duration of remission was 8.9 months (range from 1.5 to 21 + months), the average survival time 12.4 months (range from 1.5 to 21 + months, also). Two other patients showed no change lasting for two and five months respectively. In all, systemic interferon-gamma treatment applied in the manner described seems to be able to induce remissions in single cases without showing severe toxicity.
Insights
Interferon-gamma (IFN-gamma) treatment showed a 23.5% response rate in patients with metastatic malignant melanoma. This therapy induced remissions with minimal toxicity, suggesting potential for managing advanced melanoma.
Area of Science:
- Oncology
- Immunology
Background:
- Metastatic malignant melanoma presents a significant therapeutic challenge.
- Interferon-gamma (IFN-gamma) is a cytokine with known immunomodulatory and anti-tumor properties.
Purpose of the Study:
- To evaluate the efficacy and toxicity of systemically administered interferon-gamma in patients with metastatic malignant melanoma.
Main Methods:
- Seventeen patients with metastatic malignant melanoma received intravenous interferon-gamma (30-40 IU total dose) daily.
- Treatment was administered between January 1985 and June 1986.
- Response was assessed using UICC criteria, and side effects were graded according to WHO criteria.
Main Results:
- An overall response rate of 23.5% was observed, with two complete and two partial remissions.
- The average duration of remission was 8.9 months (range: 1.5-21+ months).
- Average survival time was 12.4 months (range: 1.5-21+ months).
- The primary side effect was grade I-II fever; no severe toxicity was reported.
Conclusions:
- Systemic interferon-gamma therapy can induce objective responses in a subset of patients with metastatic malignant melanoma.
- The treatment demonstrated an acceptable safety profile with manageable side effects.
- Interferon-gamma may be a viable option for selected patients with advanced melanoma.